Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment. (Optimise)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00681850
First received: May 19, 2008
Last updated: June 1, 2010
Last verified: June 2010